Inrebic FDA Approval History
Last updated by Judith Stewart, BPharm on Nov 29, 2019.
FDA Approved: Yes (First approved August 16, 2019)
Brand name: Inrebic
Generic name: fedratinib
Dosage form: Capsules
Company: Celgene Corporation
Treatment for: Myelofibrosis
Inrebic (fedratinib) is a highly selective JAK2 inhibitor for the treatment of patients with myelofibrosis.
Development timeline for Inrebic
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.